A tiny Israeli company has beaten some of the biggest medtechs in the world to the wireless charging of heart pumps.
A study of a liquid biopsy and another looking at tumour mutational burden testing give early indications of Foundation’s approval strategy.
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
Another vast trial is on the cards for Apple’s ECG, and ought to yield more meaningful data.
Will the Apple Heart Study allow early detection of arrhythmias, or drive the worried well to doctors unnecessarily? For Irhythm Technologies, either is a good outcome.
The UK ortho and woundcare group might yet pounce on Nuvasive.
A positive readout for Medtronic's Tyrx envelope could mean an extra $1,000 per cardiac implant in the company's pocket.
Guardant gets a liquid biopsy trial win, but if it wants to drive sales it must get cancer societies on board.